{"id":5787,"date":"2026-05-20T08:13:01","date_gmt":"2026-05-20T07:13:01","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=5787"},"modified":"2026-05-21T08:36:54","modified_gmt":"2026-05-21T07:36:54","slug":"yartemlea-fda-approval-ta-tma","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/","title":{"rendered":"FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant"},"content":{"rendered":"<p>Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a rare but severe complication that can occur after stem cell transplantation. The condition is characterized by the formation of microscopic blood clots in small blood vessels, potentially leading to multi-organ damage and life-threatening complications.<\/p>\n<p>At Lenus Health, we continuously follow global pharmaceutical and regulatory developments to provide valuable healthcare insights and support informed industry collaboration.<\/p>\n<p>The <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noopener\">U.S. Food and Drug Administration (FDA) official announcement<\/a> confirmed the approval of Narsoplimab (Yartemlea) injection as the first approved therapy for adults and children aged 2 years and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).<\/p>\n<p>This approval represents an important milestone in the treatment of post-transplant complications, particularly for patients with limited therapeutic options.<\/p>\n<p><strong>Table of Contents<\/strong><\/p>\n<ul>\n<li><a href=\"#Introduction\">Introduction to Yartemlea and Mechanism of Action<\/a><\/li>\n<li><a href=\"#Understanding\">Understanding TA-TMA<\/a><\/li>\n<li><a href=\"#Clinical\">Clinical Trial Evidence<\/a><\/li>\n<li><a href=\"#Dosage\">Dosage and Administration<\/a><\/li>\n<li><a href=\"#Safety\">Safety Information and Adverse Events<\/a><\/li>\n<li><a href=\"#FDA\">FDA Expedited Designations<\/a><\/li>\n<li><a href=\"#Conclusion\">Conclusion and Future Perspectives<\/a><\/li>\n<li><a href=\"#faq\">Frequently Asked Questions (FAQs)<\/a><\/li>\n<\/ul>\n<h2 id=\"Introduction\">1. Introduction to Yartemlea and Mechanism of Action<\/h2>\n<p>Narsoplimab (Yartemlea) is a monoclonal antibody designed to inhibit the lectin pathway of the complement system, which plays a significant role in endothelial injury and inflammation associated with TA-TMA.<\/p>\n<p>By targeting this pathway, the drug may help reduce microvascular injury, improve organ function, and limit further progression of thrombotic complications.<\/p>\n<h2 id=\"Understanding\">2. Understanding TA-TMA<\/h2>\n<p>Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication that may develop following stem cell transplantation.<\/p>\n<p>The condition involves:<\/p>\n<ul>\n<li>Formation of small blood clots in blood vessels<\/li>\n<li>Damage to endothelial cells<\/li>\n<li>Organ dysfunction affecting:\n<ul>\n<li>Kidneys<\/li>\n<li>Cardiovascular system<\/li>\n<li>Gastrointestinal tract<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>TA-TMA is associated with significant morbidity and mortality, especially in severe post-transplant cases.<\/p>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-01.jpg\" alt=\"Understanding TA-TMA\" width=\"100%\" height=\"auto\" \/><\/p>\n<h3 id=\"Clinical\">3. Clinical Trial Evidence<\/h3>\n<h3>3.1 TA-TMA Study<\/h3>\n<p>The efficacy of Yartemlea was evaluated in:<\/p>\n<ul>\n<li>28 patients enrolled in an open-label, single-arm clinical study<\/li>\n<li>Additional data from 19 patients included in an expanded access program<\/li>\n<\/ul>\n<p>Patients received:<\/p>\n<ul>\n<li>4 mg\/kg intravenous dosing<br \/>\nor<\/li>\n<li>370 mg intravenously once weekly<\/li>\n<\/ul>\n<h3>3.2 Primary Efficacy Endpoint<\/h3>\n<p>The primary endpoint was:<\/p>\n<p>TA-TMA Response<\/p>\n<p>Defined as:<\/p>\n<ul>\n<li>Improvement in laboratory markers:\n<ul>\n<li>Lactate dehydrogenase (LDH)<\/li>\n<li>Platelet count<\/li>\n<\/ul>\n<\/li>\n<li>Plus:\n<ul>\n<li>Organ function improvement<br \/>\nor<\/li>\n<li>Elimination of transfusion requirements<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Results:<\/p>\n<ul>\n<li>TA-TMA Study: 61% response rate<\/li>\n<li>Expanded Access Program:\n<ul>\n<li>Pediatric patients: 67%<\/li>\n<li>Adult patients: 69%<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>These findings demonstrated clinically meaningful responses in a condition with previously limited treatment options.<\/p>\n<h2 id=\"Dosage\">4. Dosage and Administration<\/h2>\n<p>Yartemlea is administered intravenously once weekly.<\/p>\n<p>Recommended dosing includes:<\/p>\n<ul>\n<li>4 mg\/kg IV<br \/>\nor<\/li>\n<li>370 mg IV weekly<\/li>\n<\/ul>\n<p>Treatment schedules should be individualized based on patient condition and clinical response.<\/p>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-00.jpg\" alt=\"Yartemlea FDA Zulassung\" width=\"100%\" height=\"auto\" \/><\/p>\n<h2 id=\"Safety\">5. Safety Information and Adverse Events<\/h2>\n<p><strong>Common Adverse Events<\/strong><\/p>\n<p>The most frequently reported side effects include:<\/p>\n<ul>\n<li>Viral infections<\/li>\n<li>Sepsis<\/li>\n<li>Hemorrhage<\/li>\n<li>Diarrhea<\/li>\n<li>Vomiting and nausea<\/li>\n<li>Neutropenia<\/li>\n<li>Fever<\/li>\n<li>Fatigue<\/li>\n<li>Low potassium levels<\/li>\n<\/ul>\n<p><strong>Important Safety Considerations<\/strong><\/p>\n<p>Patients receiving Yartemlea should be closely monitored for:<\/p>\n<ul>\n<li>Serious infections<\/li>\n<li>Hematologic complications<\/li>\n<li>Signs of worsening immunosuppression<\/li>\n<\/ul>\n<h2 id=\"FDA\">6. FDA Expedited Designations<\/h2>\n<p>Yartemlea received several important FDA regulatory designations, including:<\/p>\n<ul>\n<li>Priority Review<\/li>\n<li>Breakthrough Therapy Designation<\/li>\n<li>Orphan Drug Designation<\/li>\n<\/ul>\n<p>These programs are intended to accelerate the development and review of therapies addressing serious or rare diseases with unmet medical needs.<\/p>\n<p><strong id=\"Conclusion\">7. Conclusion and Future Perspectives<\/strong><\/p>\n<p>The approval of Narsoplimab (Yartemlea) marks a major advancement in the management of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication with historically limited treatment options.<\/p>\n<p>Clinically, the demonstrated response rates and improvements in laboratory and organ function parameters suggest that complement pathway inhibition may provide a meaningful therapeutic strategy for affected patients.<\/p>\n<p>From a regulatory perspective, the FDA\u2019s expedited review and designation programs highlight the significant unmet medical need associated with TA-TMA and the importance of accelerating innovative therapies for rare and high-risk conditions.<\/p>\n<p>Future long-term studies and real-world clinical experience will be important to further evaluate the durability of response, safety profile, and optimal positioning of Yartemlea within post-transplant care protocols.<\/p>\n<p>Overall, this approval introduces the first targeted treatment option for TA-TMA and may help improve outcomes for both pediatric and adult transplant patients.<\/p>\n<p>Lenus Health continues to monitor emerging therapies and pharmaceutical innovations shaping the future of healthcare.<\/p>\n<p><strong id=\"faq\">8. Frequently Asked Questions (FAQs)<\/strong><\/p>\n<ul>\n<li><strong>What is Yartemlea used for?<br \/>\n<\/strong>Yartemlea is approved for the treatment of TA-TMA in adults and children aged 2 years and older following stem cell transplantation.<\/li>\n<li><strong>What is TA-TMA?<br \/>\n<\/strong>TA-TMA is a serious complication after stem cell transplant involving blood clot formation in small blood vessels and organ damage.<\/li>\n<li><strong>How is Yartemlea administered?<br \/>\n<\/strong>The drug is given intravenously once weekly.<\/li>\n<li><strong>What are the most common side effects?<br \/>\n<\/strong>Common side effects include infections, sepsis, gastrointestinal symptoms, fatigue, and neutropenia.<\/li>\n<li><strong>Why is this approval important?<br \/>\n<\/strong>It is the first FDA-approved treatment specifically indicated for TA-TMA.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>First TA-TMA Treatment<\/p>\n","protected":false},"author":2,"featured_media":5783,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[120],"tags":[],"class_list":["post-5787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yartemlea FDA Approval | First TA-TMA Treatment<\/title>\n<meta name=\"description\" content=\"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yartemlea FDA Approval | First TA-TMA Treatment\" \/>\n<meta property=\"og:description\" content=\"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/\" \/>\n<meta property=\"og:site_name\" content=\"Lenus Health\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T07:13:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T07:36:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"873\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"login-hashemzadeh-dash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"login-hashemzadeh-dash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/\"},\"author\":{\"name\":\"login-hashemzadeh-dash\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\"},\"headline\":\"FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant\",\"datePublished\":\"2026-05-20T07:13:01+00:00\",\"dateModified\":\"2026-05-21T07:36:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/\"},\"wordCount\":749,\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yartemlea-FDA-TH.jpg\",\"articleSection\":[\"New medicines\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/\",\"name\":\"Yartemlea FDA Approval | First TA-TMA Treatment\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yartemlea-FDA-TH.jpg\",\"datePublished\":\"2026-05-20T07:13:01+00:00\",\"dateModified\":\"2026-05-21T07:36:54+00:00\",\"description\":\"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yartemlea-FDA-TH.jpg\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yartemlea-FDA-TH.jpg\",\"width\":1600,\"height\":873,\"caption\":\"First TA-TMA therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/yartemlea-fda-approval-ta-tma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New medicines\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/category\\\/new-medicine\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#website\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/\",\"name\":\"Lenus Health\",\"description\":\"Lenus Health Gmbh | Berlin\",\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lenus-healthcare.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\",\"name\":\"Lenus Health\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/Logo-pur.webp\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/Logo-pur.webp\",\"width\":1275,\"height\":298,\"caption\":\"Lenus Health\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\",\"name\":\"login-hashemzadeh-dash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"caption\":\"login-hashemzadeh-dash\"},\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/author\\\/login-hashemzadeh-dash\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yartemlea FDA Approval | First TA-TMA Treatment","description":"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/","og_locale":"en_US","og_type":"article","og_title":"Yartemlea FDA Approval | First TA-TMA Treatment","og_description":"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.","og_url":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/","og_site_name":"Lenus Health","article_published_time":"2026-05-20T07:13:01+00:00","article_modified_time":"2026-05-21T07:36:54+00:00","og_image":[{"width":1600,"height":873,"url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg","type":"image\/jpeg"}],"author":"login-hashemzadeh-dash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"login-hashemzadeh-dash","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#article","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/"},"author":{"name":"login-hashemzadeh-dash","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09"},"headline":"FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant","datePublished":"2026-05-20T07:13:01+00:00","dateModified":"2026-05-21T07:36:54+00:00","mainEntityOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/"},"wordCount":749,"publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg","articleSection":["New medicines"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/","url":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/","name":"Yartemlea FDA Approval | First TA-TMA Treatment","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#primaryimage"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg","datePublished":"2026-05-20T07:13:01+00:00","dateModified":"2026-05-21T07:36:54+00:00","description":"Yartemlea FDA approval TA-TMA | FDA approves the first treatment for stem cell transplant-associated thrombotic microangiopathy.","breadcrumb":{"@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#primaryimage","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/05\/Yartemlea-FDA-TH.jpg","width":1600,"height":873,"caption":"First TA-TMA therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/lenus-healthcare.com\/en\/yartemlea-fda-approval-ta-tma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lenus-healthcare.com\/en\/home\/"},{"@type":"ListItem","position":2,"name":"New medicines","item":"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/"},{"@type":"ListItem","position":3,"name":"FDA Approves Yartemlea: First Approved Treatment for TA-TMA After Stem Cell Transplant"}]},{"@type":"WebSite","@id":"https:\/\/lenus-healthcare.com\/#website","url":"https:\/\/lenus-healthcare.com\/","name":"Lenus Health","description":"Lenus Health Gmbh | Berlin","publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lenus-healthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lenus-healthcare.com\/#organization","name":"Lenus Health","url":"https:\/\/lenus-healthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","width":1275,"height":298,"caption":"Lenus Health"},"image":{"@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09","name":"login-hashemzadeh-dash","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","caption":"login-hashemzadeh-dash"},"url":"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/"}]}},"_links":{"self":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/5787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/comments?post=5787"}],"version-history":[{"count":2,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/5787\/revisions"}],"predecessor-version":[{"id":5792,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/5787\/revisions\/5792"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media\/5783"}],"wp:attachment":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media?parent=5787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/categories?post=5787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/tags?post=5787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}